Search
    • Apr 21
    • 1 min read

ASCO 2020 [May29 > Jun02]

Updated: Aug 9

We'll be there for you!



For our next participation at the ASCCO congress, we will be there to present you:

EBioMedicine by THE LANCET

  • Latest results from work with numerous partners on the usefulness of targeting hPG80 for multiple cancers

  • Our DxPG80 IVD test for the detection and assay of hPG80 in blood plasma, which began commercialization and clinical operations in late 2019.

  • And finally, this seminal scientific publication published in the scientific press on the overexpression of hPG80 (circulating extracellular progastrin) in multiple cancers.

We are pleased to share this good news with you, the fruit of the many partnerships we have entered into together.


Happy to see you soon in Chicago!



IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

​

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

​

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

​

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

​

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

​

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved